NDA 202570 · Pf Prism Cv
Xalkori
Crizotinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 7, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Aug 26, 2011
Approved uses
9
Original approval plus efficacy supplements
Registered trials
148
25 Phase 3, 14 recruiting
FAERS reports
12,739
9,350 serious, 3,853 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2026.
XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. ( 1.3 , 2.3 ) 1.1 ALK- or ROS1-Positive Metastatic Non-Small Cell Lung Cancer XALKORI is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . 1.2 Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma XALKORI is indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive . Limitations of Use : The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. 1.3 Unresectable, Recurrent, or Refractory ALK-Positive Inflammatory Myofibroblastic Tumor XALKORI is indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.
Mechanism: Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d'Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene's expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 7, 2023 Supplement 36 · Efficacy OrphanLabelLetterMedication Guide
- Jul 14, 2022 Supplement 33 · Efficacy · priority review OrphanLabelLetter
- Jan 14, 2021 Supplement 30 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Nov 30, 2018 Supplement 26 · Efficacy OrphanLabelLetter
- Apr 28, 2017 Supplement 19 · Efficacy OrphanLabelLetter
- Mar 11, 2016 Supplement 16 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Sep 14, 2015 Supplement 14 · Efficacy OrphanLabelLetter
- Nov 20, 2013 Supplement 6 · Efficacy OrphanLabelLetter
- Aug 26, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanSummary ReviewLetterLabel
2 products under this application
- XALKORI · CRIZOTINIB 250MG · CAPSULE, ORAL · Prescription
- XALKORI · CRIZOTINIB 200MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Crizotinib" as an intervention, any sponsor and status, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid TumorsActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT07891169 · 2,800 participants (planned) · Start Nov 18, 2024 · Primary completion Dec 31, 2028
Drug: Homologous Recombination Deficiency (HRD); ALK/ROS1/MET and 1 more · For: Advanced Solid Tumors; Metastatic Solid Tumors; Locally Advanced Solid Tumors and 4 more
Sites: Goyang, South Korea; Goyang-si, South Korea
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Molecularly Tailored Therapy in Advanced Pancreatic CancerPivotal-lookingNot yet recruiting
Herlev HospitalAcademic, hospital or other
NCT07802418 · 1,200 participants (planned) · Start Oct 2026 · Primary completion Jun 2031
Drug: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy and 1 more · For: Pancreatic Cancer
Sites: Aalborg, Denmark; Aarhus, Denmark; Herlev, Denmark · 4 sites in all
PfizerPfizer (PFE)
NCT00932451 · 1,069 participants · Start Jan 2010 · Primary completion Mar 2015
Drug: PF-02341066 · For: Carcinoma, Non-Small-Cell Lung
Sites: Birmingham, Alabama; Little Rock, Arkansas; Bakersfield, California · 280 sites in all
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death2,379
- disease progression1,217
- nausea1,124
- neoplasm progression1,110
- diarrhoea849
- vomiting799
- fatigue557
- off label use474
- oedema peripheral449
- constipation442
- dyspnoea432
- lung neoplasm malignant420
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 109 |
| 2012 | 774 |
| 2013 | 1,097 |
| 2014 | 1,298 |
| 2015 | 1,195 |
| 2016 | 1,140 |
| 2017 | 1,012 |
| 2018 | 1,024 |
| 2019 | 1,074 |
| 2020 | 813 |
| 2021 | 661 |
| 2022 | 660 |
| 2023 | 629 |
| 2024 | 587 |
| 2025 | 407 |
| 2026 | 259 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xalkori (Crizotinib)
2024 spending
$58.9M
Beneficiaries
406
2,952 claims
Per beneficiary
$145,013
$365.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $62,640,524 |
| 2021 | $53,046,547 |
| 2022 | $58,588,555 |
| 2023 | $52,137,023 |
| 2024 | $58,875,150 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Shaw AT, Solomon BJ, Felip E, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S, Camidge DR, Shaw AT, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR, Kim HR, Ahn MJ, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Comparative Study
Sponsor: Pf Prism Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.